Categories
Change Password!
Reset Password!
This study determined the short-term effectiveness of semaglutide for weight loss and evaluated changes in body weight and body mass index (BMI) at 1 and 3 months in patients with obesity under real-world clinical conditions.
Obesity patients experience rapid, clinically relevant weight loss and BMI decline with semaglutide in just 3 months.
This study determined the short-term effectiveness of semaglutide for weight loss and evaluated changes in body weight and body mass index (BMI) at 1 and 3 months in patients with obesity under real-world clinical conditions.
In this retrospective cohort study, 170 adults with obesity who initiated semaglutide therapy at two tertiary care hospitals were included. Only those with high treatment adherence and complete follow-up at 1 and 3 months were analyzed. Key outcomes included changes in body weight and BMI, assessed using repeated measures analysis of variance (ANOVA).
Patients had a mean baseline weight of 104.97 ± 14.53 kg and a mean BMI of 37.07 ± 4.38 kg/m². By month 3, mean body weight dropped significantly to 96.04 ± 13.92 kg, while BMI declined to 33.92 ± 4.20 kg/m². Both weight and BMI reductions were statistically significant at each follow-up point (p<0.001). Overall, patients attained an average weight loss of 8.51% within 3 months of semaglutide treatment.
Semaglutide illustrated strong short-term efficacy for weight reduction and BMI improvement in obesity management. High adherence was linked with clinically meaningful weight loss, supporting its growing role in real-world obesity treatment strategies.
Dicle Medical Journal
Evaluation of Short-Term (1st and 3rd Month) Anthropometric Results in Obesity Patients Initiating Semaglutide Treatment: Experience of Two Tertiary Centers
Eşref Araç et al.
Comments (1)